{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:02:12Z","timestamp":1792627332298,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Literature indicates adverse effects of lithium on thyroid and kidney function. However, existing data are heterogeneous, with limitations in quality and lack evaluation of adverse effects of lithium vs other mood stabilizers, especially commonly prescribed second-generation antipsychotics. Lithium serum level thresholds associated with thyroid and kidney abnormalities remain unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine risk of thyroid and kidney dysfunction in patients with incident bipolar disorder (BD) treated with lithium and other mood stabilizers and antipsychotics in an Asian population and to determine lithium serum level cutoffs associated with these physical complications.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based retrospective cohort study identified patients aged 15 years or older with first-diagnosed BD in Hong Kong from 2002 to 2018, utilizing a medical record database of public health care services. Data analysis was performed from February to May 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Lithium vs nonlithium treatment. The nonlithium group was further stratified into valproate, olanzapine, quetiapine, and risperidone groups.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Main outcomes were hypothyroidism, hyperthyroidism, and chronic kidney disease stage 3 or higher (CKD3+), with additional investigation on CKD stage 4 or higher (CKD4+) and end-stage kidney disease (ESKD). Outcomes were ascertained using laboratory test results. Cox proportional hazards regression analyses were performed for risk estimation with adjusted hazard ratios (aHRs) and 95% CIs. Receiver operating characteristic analyses with the Youden index were employed to determine lithium serum level cutoffs associated with thyroid and kidney dysfunction.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 4752 individuals with analyzable data for hypothyroidism (mean [SD] age, 39.5 [15.6] years; mean [SD] follow-up, 8.4 [4.8] years; 2889 female [60.8%]), 4500 with data for hyperthyroidism (mean [SD] age, 39.7 [15.6] years; mean [SD] follow-up, 8.7 [4.7] years; 2716 female [60.4%]), and 7029 with data for CKD (mean [SD] age, 37.9 [14.8] years; mean [SD] follow-up, 8.3 [4.8] years; 4251 female [60.5%]). Lithium was associated with increased risk of hypothyroidism (aHR, 2.00; 95% CI, 1.72-2.33) and CKD3+ (aHR, 1.35; 95% CI, 1.15-1.60), but not CKD4+ or ESKD, compared with nonlithium treatments. Higher lithium serum levels were associated with elevated rates of hypothyroidism (aHR, 2.08; 95% CI, 1.67-2.59), hyperthyroidism (aHR, 1.81; 95% CI, 1.31-2.50), and CKD3+ (aHR, 2.11; 95% CI, 1.57-2.85). Greater number of lithium toxicity episodes was associated with increased CKD3+ risk. Valproate, olanzapine, quetiapine, and risperidone generally exhibited reduced likelihood of thyroid dysfunction and CKD3+ compared with lithium, without any difference in advanced CKD. Mean lithium serum levels greater than 0.5028 mEq\/L, greater than 0.5034 mEq\/L, and greater than 0.5865 mEq\/L represented thresholds associated with hypothyroidism, hyperthyroidism, and CKD3+, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with incident BD, lithium was associated with a mildly increased risk of thyroid dysfunction and CKD in a predominantly Chinese population. The identified lithium level thresholds associated with risks of physical complications may facilitate the development of evidence-based guidelines recommending lithium treatment, particularly in Asian populations, and the promotion of personalized care and risk-benefit balancing in the treatment for BD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.58608","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:03:51Z","timestamp":1739271831000},"page":"e2458608","source":"Crossref","is-referenced-by-count":29,"title":["Lithium for Bipolar Disorder and Risk of Thyroid Dysfunction and Chronic Kidney Disease"],"prefix":"10.1001","volume":"8","author":[{"given":"Joe Kwun Nam","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[{"name":"SCIENCES Lab, Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Regional Centre for the Treatment of Eating Disorders, Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"},{"name":"On Track: The Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"},{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine Sau","family":"Man Wong","sequence":"additional","affiliation":[{"name":"School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Ka Ying","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"Laboratory of Data Discovery for Health, Hong Kong Science Park, Sha Tin, Hong Kong SAR, China"},{"name":"Advanced Data Analytics for Medical Science Limited, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Chung","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China"},{"name":"State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"2","key":"zoi241640r1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"issue":"5","key":"zoi241640r2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1192\/bjp.2022.54","article-title":"Effectiveness of medical treatment for bipolar disorder regarding suicide, self-harm and psychiatric hospital admission: between- and within-individual study on Danish national data.","volume":"221","author":"Fitzgerald","year":"2022","journal-title":"Br J Psychiatry"},{"issue":"7","key":"zoi241640r3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/bdi.12543","article-title":"Lithium and suicide in mood disorders: updated meta-review of the scientific literature.","volume":"19","author":"Smith","year":"2017","journal-title":"Bipolar Disord"},{"issue":"1","key":"zoi241640r4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/bdi.13366","article-title":"Patterns of pharmacotherapy for bipolar disorder: a GBC survey.","volume":"26","author":"Singh","year":"2024","journal-title":"Bipolar Disord"},{"issue":"8","key":"zoi241640r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002058","article-title":"Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study.","volume":"13","author":"Hayes","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"zoi241640r6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bdi.13356","article-title":"Association between lithium treatment and renal, thyroid and parathyroid function: a cohort study of 6659 patients with bipolar disorder.","volume":"26","author":"Wiuff","year":"2024","journal-title":"Bipolar Disord"},{"issue":"3","key":"zoi241640r7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bdi.13154","article-title":"Prevalence of impaired kidney function in patients with long-term lithium treatment: a systematic review and meta-analysis.","volume":"24","author":"Schoretsanitis","year":"2022","journal-title":"Bipolar Disord"},{"issue":"7","key":"zoi241640r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22056","article-title":"Absolute and relative risks of kidney outcomes associated with lithium vs valproate use in Sweden.","volume":"6","author":"Bosi","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi241640r10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40345-022-00249-5","article-title":"Estimated glomerular filtration rate in Korean patients exposed to long-term lithium maintenance therapy.","volume":"10","author":"Cho","year":"2022","journal-title":"Int J Bipolar Disord"},{"issue":"9992","key":"zoi241640r11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(14)61842-0","article-title":"Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data.","volume":"386","author":"Shine","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"zoi241640r12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2215-0366(15)00316-8","article-title":"Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study.","volume":"2","author":"Clos","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"zoi241640r13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2215-0366(22)00265-6","article-title":"Kidney function in patients with bipolar disorder with and without lithium treatment compared with the general population in northern Sweden: results from the LiSIE and MONICA cohorts.","volume":"9","author":"Fransson","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"zoi241640r14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/brainsci13010133","article-title":"Long-term lithium therapy and thyroid disorders in bipolar disorder: a historical cohort study.","volume":"13","author":"Joseph","year":"2023","journal-title":"Brain Sci"},{"issue":"5","key":"zoi241640r15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13045","article-title":"Association of lithium use and a higher serum concentration of lithium with the risk of declining renal function in older adults: a population-based cohort study.","volume":"81","author":"Rej","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"zoi241640r16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euroneuro.2014.01.002","article-title":"End-stage renal disease associated with prophylactic lithium treatment.","volume":"24","author":"Aiff","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"zoi241640r17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamapsychiatry.2015.1834","article-title":"Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study.","volume":"72","author":"Kessing","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"zoi241640r19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"9817","key":"zoi241640r20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","article-title":"Lithium toxicity profile: a systematic review and meta-analysis.","volume":"379","author":"McKnight","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"zoi241640r21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0004867419833171","article-title":"Lithium can cause hyperthyroidism as well as hypothyroidism: a systematic review of an under-recognised association.","volume":"53","author":"Fairbrother","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"zoi241640r22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bdi.13298","article-title":"Evaluation of thyroid function monitoring in people treated with lithium: advice based on real-world data.","volume":"25","author":"Duce","year":"2023","journal-title":"Bipolar Disord"},{"issue":"2","key":"zoi241640r23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bcpt.13758","article-title":"Lithium and the risk of chronic kidney disease: a population-based case-control study.","volume":"131","author":"H\u00f8jlund","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"zoi241640r24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40345-023-00319-2","article-title":"Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study.","volume":"11","author":"Golic","year":"2023","journal-title":"Int J Bipolar Disord"},{"issue":"5","key":"zoi241640r25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bdi.12805","article-title":"What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD\/IGSLI Task Force on treatment with lithium.","volume":"21","author":"Nolen","year":"2019","journal-title":"Bipolar Disord"},{"issue":"10","key":"zoi241640r26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40263-022-00952-y","article-title":"Psychotropic drugs and adverse kidney effects: a systematic review of the past decade of research.","volume":"36","author":"Damba","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"zoi241640r27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0000000000001632","article-title":"Real-world clinical practice among patients with bipolar disorder and chronic kidney disease on long-term lithium therapy.","volume":"43","author":"Kumar","year":"2023","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"zoi241640r28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/npp.2015.254","article-title":"Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study.","volume":"41","author":"Castro","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"zoi241640r29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.13346","article-title":"Lithium concentration and recurrence risk during maintenance treatment of bipolar disorder: multicenter cohort and meta-analysis.","volume":"144","author":"Hsu","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"zoi241640r30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ajp.2012.01.003","article-title":"Ethnopsychopharmacology considerations for Asians and Asian Americans.","volume":"5","author":"Wong","year":"2012","journal-title":"Asian J Psychiatr"},{"issue":"1","key":"zoi241640r31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40345-017-0089-1","article-title":"An observational study of 110 elderly lithium-treated patients followed up for 6 years with particular reference to renal function.","volume":"5","author":"Bocchetta","year":"2017","journal-title":"Int J Bipolar Disord"},{"issue":"1","key":"zoi241640r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40345-020-00204-2","article-title":"Chronic kidney disease in lithium-treated patients, incidence and rate of decline.","volume":"9","author":"Van Alphen","year":"2021","journal-title":"Int J Bipolar Disord"},{"issue":"7","key":"zoi241640r33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/13607863.2014.888536","article-title":"Renal function in geriatric psychiatry patients compared to non-psychiatric older adults: effects of lithium use and other factors.","volume":"18","author":"Rej","year":"2014","journal-title":"Aging Ment Health"},{"issue":"3","key":"zoi241640r34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/bdi.12391","article-title":"Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort.","volume":"18","author":"Lambert","year":"2016","journal-title":"Bipolar Disord"},{"issue":"1","key":"zoi241640r35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000535777","article-title":"Mortality and lithium-protective effects after first-episode mania diagnosis in bipolar disorder: a nationwide retrospective cohort study in Taiwan.","volume":"93","author":"Carvalho","year":"2024","journal-title":"Psychother Psychosom"},{"key":"zoi241640r18","volume-title":"Clinical Data Analysis & Reporting System (CDARS) User\u2019s Manual","author":"Hospital Authority Head Office IT Department","year":"2003","edition":"2nd ed."},{"key":"zoi241640r8","unstructured":"National Institute for Health Care and Excellence. Bipolar disorder: assessment and management. Published September 24, 2014. Updated December 21, 2023. Accessed May 17, 2024. https:\/\/www.nice.org.uk\/guidance\/cg185"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830093\/chan_2025_oi_241640_1738355170.97899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:04:02Z","timestamp":1739271842000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.58608","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}